The pioneering AI molecular drug design platform is growing and is expected to support its further research with the funds.
On April 12, 2021, StoneWise announced it had raised over USD 100 million in a Series B and a Series B+, jointly led by Legend Capital, Greater Bay Area Homeland Investments and Lightspeed China, followed by CDG VGC, Eastern Bell Capital, SIG Asia, Long Hill Capital and Linear Capital. The funding will be used to further attract the world's top talents, consolidate the industrialization of AI platforms and accelerate the iteration speed.
Founded in 2018, StoneWise is a technology company focusing on artificial intelligence for new drug research. It has been committed to building a great small molecule innovative drug service platform, providing innovative drug design solutions such as medical knowledge mapping, molecular generation and design, activity prediction and ADMET prediction.
In the past year, the company's AI molecular design software platform has achieved breakthrough test results in a short time, in highly difficult First-in-class and Fast-follow projects. Many companies have signed cooperation agreements with it, including BeyondSpring, Peking University Health Science Center and Institute of Material Medica Chinese Academy of Medical Science (IMM) – all owing to the good test results it achieved in the early stages. At present, its product has been purchased by many top scientific research institutions and pharmaceutical companies, making it the first commercial AI molecular drug design software success story in China. StoneWise is a company to watch in AI molecular drug sector and we expected its further growth opportunity.